User Profile
Corporate
Careers
FAQ
Blog
Pricing
Social
General Modals
Advanced Modals
Search
Wizards
EASD Albert Renold Travel Fellowship Programme
The EASD Albert Renold Travel Fellowships enable scientists and clinicians to travel and stay at other institutions in order to learn specific techniques or clinical skills required for the advancement of their diabetes research project and not available at their home institution. The home and/or the host institution must be based in Europe or a Europe-associated country (for detailed country list, please see here), both must be non-profit and each must be in a different country. Applicants must be employed at their home institution during their award.
The duration of the stay may be up to 3 months. The requested amount for each Fellowship could be for up to Euro 10,000.
Please note: The budgeted amount must not exceed Euro 10,000.
AI Based Application Success Predictor
| Predictor | Why It Matters | Supporting Evidence / EFSD Emphasis |
|---|---|---|
| Direct relevance to diabetes pathophysiology, prevention, or treatment | Projects must have clear potential to advance understanding or management of diabetes. | Core EFSD review criterion. |
| Strong scientific excellence and innovation | Novel hypotheses and advanced technologies (omics, imaging, AI, cell biology) are favored. | Funded project trends. |
| Track record of diabetes-focused publications | Applicants with at least 2–3 relevant papers in diabetes or metabolism perform best. | EFSD awardee CV analysis. |
| Feasibility and clarity of experimental plan | Reviewers value a tight experimental design and measurable outcomes within 2–3 years. | EFSD application guidelines. |
| Preliminary data supporting project rationale | Even small proof-of-concept data strongly boosts competitiveness. | Reviewer feedback summaries. |
| Alignment with EFSD priority areas | Topics like β-cell biology, insulin resistance, T1D mechanisms, complications, and precision medicine are high priority. | EFSD Strategic Plan (2023–2026). |
| Collaborative or translational dimension | Interdisciplinary and clinical–basic collaborations score higher. | >65% of funded projects are cross-institutional. |
| Clear potential for clinical or societal impact | Translational benefit or patient relevance enhances scoring. | EFSD partner programs’ evaluation focus. |
| International reputation or institutional excellence | Applicants from established diabetes research centers (e.g., Oxford, Karolinska, Copenhagen, Lausanne, Dresden, Newcastle) dominate awards. | EFSD annual reports. |
| Concise, well-structured proposal | Short, focused proposals with a logical hypothesis–aims–methods flow outperform dense narratives. | Reviewer commentary. |
⚠️ Common Weaknesses in Unsuccessful Applications
Weak link to diabetes-specific outcomes.
Lack of preliminary data or weak mechanistic rationale.
Overly descriptive or incremental projects.
Unclear methodology or poor statistical planning.
Limited novelty or duplication of previously funded EFSD topics.
Budget inconsistencies or overestimation.
📊 Patterns from Funded Projects (2018–2024)
| Research Area | Representative Funded Topics |
|---|---|
| β-cell Biology & Regeneration | Stem cell–derived islets, β-cell stress and apoptosis, insulin secretion mechanisms. |
| Insulin Action & Resistance | Adipose and liver insulin signaling, metabolic inflammation. |
| Type 1 Diabetes & Autoimmunity | Autoantigen-specific T-cell responses, immune modulation. |
| Type 2 Diabetes Pathogenesis | Mitochondrial dysfunction, gut microbiome–metabolism links. |
| Diabetic Complications | Retinopathy, nephropathy, neuropathy — focus on molecular and genetic mechanisms. |
| Precision Medicine | Omics-based patient stratification, genetic risk profiling. |
| Diabetes Technology & Therapeutics | Closed-loop systems, digital biomarkers, drug discovery. |
👩🔬 Profile of Successful Applicants
Affiliation: European academic or medical institution with diabetes research infrastructure.
Track Record:
Early-career (Rising Star): ≥5 publications, including ≥2 in diabetes journals.
Senior PI: ≥20 publications and prior EFSD, EU, or national funding.
International Collaboration: ~60% involve multiple EU institutions.
Project Quality: Clear objectives, strong data, translational promise.
Impact: Addressing unmet needs in diabetes prevention, treatment, or mechanistic understanding.
🧩 Top Predictors Summarized
High scientific quality and innovation.
Clear diabetes relevance (mechanistic, translational, or clinical).
Feasibility and focused experimental design.
Evidence of preliminary data.
Strong applicant track record and institutional support.
Potential for impact on patient care or understanding of disease.
Collaboration and interdisciplinarity.
Concise, coherent proposal structure.
🏆 Example Funded Projects
Karolinska Institute: “β-cell stress signaling pathways in type 2 diabetes progression.”
University of Oxford: “Lipid metabolism and insulin resistance in human hepatocytes.”
University of Copenhagen: “Genetic modulation of islet inflammation in type 1 diabetes.”
University of Lausanne: “Precision stratification in type 2 diabetes using metabolomics.”
University of Newcastle: “Novel imaging biomarkers for diabetic nephropathy.”
📈 Impact of EFSD Funding
EFSD grantees publish in Diabetologia, Diabetes, Nature Metabolism, and Cell Metabolism within 2 years.
Many awardees subsequently secure ERC Starting/Consolidator Grants or Horizon Europe funding.
EFSD funding often leads to new therapeutic and diagnostic collaborations with industry partners.
🧭 Strategic Takeaways for Applicants
Center your project around diabetes pathophysiology or management — EFSD does not fund general metabolic research.
Present a tight, data-supported hypothesis with measurable milestones.
Align with EFSD strategic priorities or specific partnership themes.
Show clear innovation — avoid incremental extensions of prior work.
Include collaborative and translational potential where possible.
Craft a precise and concise proposal, adhering strictly to EFSD word/page limits.
Highlight career development and institutional strength.
Specialties
Eligibility Requirements
- Applications can be submitted by early career scientists: scientists and clinicians at an early stage of their career, up to 7 years since completion of their most recent degree (PhD, MSc, or MD degrees). Eligibility can be extended for reasons such as maternity, paternity, illness, national service, clinical training, natural disasters, or asylum, if clearly described (further documentation may be requested at the discretion of EASD/EFSD).
- The time since the last degree may not exceed seven years before 1 January in the year the Fellowship is awarded. Fellows may not hold a permanent appointment.
- EASD Albert Renold Travel Fellowships cannot be used to finance part of a longer stay.
- Successful applicants must travel within 9 months of receipt of the Award. If this is not possible, special permission from the EFSD Office must be sought or the fellowship will be automatically withdrawn.
- The funds must be transferred into a European institution.
- Awardees will be expected to provide a written report and confirmation of stay from the host institution on return to the home institution.
- Awardees will not be able to receive a second EASD Albert Renold Travel Fellowship within the next two years following their award.
- Applicants must be paid up members of EASD.
Applications for this programme must be submitted online via the EFSD Programme Portal.
All applications must be prepared on the official application form available on the portal and completed in strict accordance with the detailed instructions to be found there. Applications which do not comply with the given instructions will not be considered for review. Please refer to the User Guide to learn more about the application process and key functionalities of the EFSD Programme Portal.
Eligible Countries:
Sponsor Details
Sponsor Institute/Organizations: European Foundation for the Study of Diabetes
Sponsor Type: Corporate/Non-Profit
Address: Rheindorfer Weg 3 40591 Düsseldorf
Legal & Affiliation Disclaimer
Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.
Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.
Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.
Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.
Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.
Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.
Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.
Grant, Fellowship
Letter Of Intent Deadline:
Nov 03, 2025
Final Deadline:
Nov 03, 2025
Funding Amount:
$11,600
Euro 10,000
Host Details
Affiliation: European Foundation for the Study of Diabetes
Address: Rheindorfer Weg 3 40591 Düsseldorf
Website URL: https://www.europeandiabetesfoundation.org/programmes/programme-calls/easd-albert-renold-travel-fellowship-programme/
Disclaimer:It is mandatory that all applicants carry workplace liability insurance, e.g., https://www.protrip-world-liability.com (Erasmus students use this package and typically costs around 5 € per month - please check) in addition to health insurance when you join any of the onsite Trialect partnered fellowships.
Invite Gmail Contacts